Evaluation of immunomodulatory effects of lamotrigine in BALB/c mice

Author:

Abu-Rish Eman Y.1,Elhayek Shada Y.1,Mohamed Yehia S.23,Hamad Islam4,Bustanji Yasser15

Affiliation:

1. Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy The University of Jordan, Amman 11942, Jordan

2. Department of Medical Microbiology College of Medicine, University of Dammam, Dammam 31451 PO Box 2114, Saudi Arabia

3. Department of Microbiology and Immunology, Faculty of Pharmacy Al-Azhar University, Egypt

4. Department of Pharmacy American University of Madaba PO Box 2882, Amman 11821, Jordan

5. Hamdi Mango Center for Scientific Research, The University of Jordan Amman , Jordan

Abstract

Abstract Modulation of the immune system has recently been shown to be involved in the pharmacological effects of old antiepileptic drugs and in the pathogenesis of epilepsy. Therefore, the most recent guidelines for immunotoxicological evaluation of drugs were consulted to investigate the immunomodulatory effects of lamotrigine, a newer antiepileptic drug, in BALB/c mice. These included the in vivo effects of lamotrigine on delayed-type hypersensitivity (DTH) response to sheep red blood cell (SRBC) antigens, hemagglutination titer assays and hematological changes. In vitro effects of lamotrigine on ConA-induced splenocyte proliferation and cytokine secretion were assessed. The results showed that lamotrigine treatment significantly increased the DTH response to SRBC in the mouse model of this study. This was accompanied by a significant increase in relative monocyte and neutrophil counts and in spleen cellularity. Lamotrigine significantly inhibited ConA-induced splenocyte proliferation in vitro and it significantly inhibited IL-2 and TNF-α secretion in ConA-stimulated splenocytes. In conclusion, the results demonstrated significant immunomodulatory effects of lamotrigine in BALB/c mice. These data could expand the understanding of lamotrigine-induced adverse reactions and its role in modulating the immune system in epilepsy.

Publisher

Walter de Gruyter GmbH

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Reference31 articles.

1. 1. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Department of Health and Human Services, Guidance for Industry: Immunotoxicology Evaluation of Investigational New Drugs, October 2002; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079239.pdf; last access date July 9, 2017.

2. 2. International Conference on Harmonisation, Harmonised Tripartite Guideline: Immunotoxicity Studies for Human Pharmaceuticals S8, May 2005; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002851.pdf; last access date July 9, 2017.

3. 3. M. Collinge, L. A. Burns-Naas, G. J. Chellman, T. T. Kawabata, W. J. Komocsar, J. R. Piccotti, J. Shenton and D. Wierda, Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, state of the science, knowledge gaps, and recommendations, J. Immunotoxicol. 9 (2012) 210-230; https://doi.org/10.3109/1547691X.2012.661486

4. 4. B. Blaszczyk, W. Lason and S. J. Czuczwar, Antiepileptic drugs and adverse skin reactions: An update, Pharmacol. Rep. 67 (2015) 426-434; https://doi.org/10.1016/j.pharep.2014.11.009

5. 5. T. Shimada, T. Takemiya, H. Sugiura and K. Yamagata, Role of inflammatory mediators in the pathogenesis of epilepsy, Mediators Inflam. 2014 (2014), Article 901902 (8 pages); https://doi.org/10.1155/2014/901902

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3